Investigating how NRF2 signaling contributes to a specific type of kidney cancer
Molecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinoma
This study is looking at a tough type of kidney cancer called translocation renal cell carcinoma (tRCC) to find out how it grows and survives, with the hope of discovering new treatments that could help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10881882 on NIH RePORTER |
What this research studies
This research focuses on translocation renal cell carcinoma (tRCC), a particularly aggressive form of kidney cancer that arises from a gene fusion involving a transcription factor. The study aims to understand the molecular mechanisms that activate NRF2 signaling in tRCC, which is crucial for the cancer's growth and survival. By identifying how this pathway is regulated differently in tRCC compared to other cancers, the researchers hope to discover new therapeutic targets. Patients may benefit from potential new treatments specifically designed to target the unique biology of their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with translocation renal cell carcinoma.
Not a fit: Patients with other types of renal cell carcinoma or those without a diagnosis of kidney cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies for patients with translocation renal cell carcinoma.
How similar studies have performed: While NRF2 signaling has been studied in other cancers, this research explores a novel regulatory mechanism specific to translocation renal cell carcinoma, making it a unique approach.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Viswanathan, Srinivas Raghavan — Dana-Farber Cancer Inst
- Study coordinator: Viswanathan, Srinivas Raghavan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.